| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Staphylococcal Infections | 56 | 2023 | 672 | 9.120 |
Why?
|
| Staphylococcus aureus | 52 | 2023 | 548 | 8.430 |
Why?
|
| Pneumococcal Infections | 20 | 2022 | 241 | 6.700 |
Why?
|
| Streptococcus pneumoniae | 22 | 2023 | 330 | 5.190 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 26 | 2023 | 308 | 4.040 |
Why?
|
| Pneumococcal Vaccines | 13 | 2019 | 161 | 3.700 |
Why?
|
| Anti-Bacterial Agents | 54 | 2023 | 2992 | 3.090 |
Why?
|
| Community-Acquired Infections | 25 | 2018 | 285 | 2.800 |
Why?
|
| Osteomyelitis | 11 | 2019 | 236 | 2.720 |
Why?
|
| Microbial Sensitivity Tests | 40 | 2023 | 994 | 2.710 |
Why?
|
| Hospitals, Pediatric | 12 | 2020 | 773 | 1.930 |
Why?
|
| Serogroup | 9 | 2022 | 50 | 1.840 |
Why?
|
| Cross Infection | 13 | 2021 | 544 | 1.790 |
Why?
|
| Bacteremia | 14 | 2021 | 689 | 1.720 |
Why?
|
| Helicobacter pylori | 12 | 2021 | 1295 | 1.480 |
Why?
|
| Arthritis, Infectious | 4 | 2018 | 68 | 1.470 |
Why?
|
| Methicillin Resistance | 18 | 2015 | 147 | 1.450 |
Why?
|
| Anti-Infective Agents, Local | 4 | 2019 | 121 | 1.350 |
Why?
|
| Child | 68 | 2023 | 29154 | 1.310 |
Why?
|
| Child, Preschool | 55 | 2023 | 16273 | 1.270 |
Why?
|
| Drug Resistance, Bacterial | 12 | 2021 | 418 | 1.260 |
Why?
|
| Meningitis, Bacterial | 3 | 2021 | 89 | 1.250 |
Why?
|
| Prosthesis-Related Infections | 2 | 2020 | 232 | 1.190 |
Why?
|
| Meningitis, Pneumococcal | 2 | 2018 | 36 | 1.190 |
Why?
|
| Adhesins, Bacterial | 5 | 2020 | 85 | 1.150 |
Why?
|
| Helicobacter Infections | 8 | 2021 | 1216 | 1.150 |
Why?
|
| Infant | 45 | 2021 | 13310 | 1.090 |
Why?
|
| Multilocus Sequence Typing | 9 | 2023 | 58 | 1.090 |
Why?
|
| Streptococcal Infections | 2 | 2021 | 280 | 1.070 |
Why?
|
| Leukocidins | 12 | 2018 | 46 | 1.070 |
Why?
|
| Exotoxins | 12 | 2018 | 77 | 1.040 |
Why?
|
| Organ Transplantation | 2 | 2016 | 191 | 0.910 |
Why?
|
| Bacterial Toxins | 12 | 2018 | 228 | 0.900 |
Why?
|
| Soft Tissue Infections | 6 | 2020 | 102 | 0.890 |
Why?
|
| Sinusitis | 3 | 2014 | 131 | 0.890 |
Why?
|
| Haemophilus Infections | 2 | 2021 | 103 | 0.870 |
Why?
|
| Haemophilus influenzae | 2 | 2021 | 144 | 0.870 |
Why?
|
| Serotyping | 12 | 2022 | 166 | 0.860 |
Why?
|
| Vaccines, Conjugate | 4 | 2019 | 76 | 0.850 |
Why?
|
| Hospitalization | 5 | 2021 | 2083 | 0.840 |
Why?
|
| Genes, Bacterial | 3 | 2020 | 236 | 0.820 |
Why?
|
| Paraffin Embedding | 2 | 2021 | 226 | 0.810 |
Why?
|
| Carrier State | 3 | 2011 | 90 | 0.810 |
Why?
|
| Ribotyping | 1 | 2021 | 48 | 0.790 |
Why?
|
| Texas | 27 | 2021 | 6311 | 0.790 |
Why?
|
| Tissue Fixation | 1 | 2021 | 136 | 0.780 |
Why?
|
| Cefazolin | 1 | 2020 | 25 | 0.760 |
Why?
|
| Gastric Mucosa | 2 | 2021 | 613 | 0.750 |
Why?
|
| Staphylococcal Scalded Skin Syndrome | 1 | 2020 | 8 | 0.730 |
Why?
|
| Genes, MDR | 1 | 2019 | 38 | 0.690 |
Why?
|
| Mycobacterium avium subsp. paratuberculosis | 5 | 2001 | 17 | 0.680 |
Why?
|
| Adolescent | 40 | 2021 | 31252 | 0.680 |
Why?
|
| Infant, Newborn | 23 | 2021 | 8223 | 0.660 |
Why?
|
| Methicillin | 5 | 2023 | 49 | 0.660 |
Why?
|
| Orbital Cellulitis | 1 | 2018 | 18 | 0.650 |
Why?
|
| Biofilms | 1 | 2020 | 199 | 0.650 |
Why?
|
| Humans | 118 | 2023 | 261506 | 0.650 |
Why?
|
| Virulence Factors | 6 | 2020 | 213 | 0.640 |
Why?
|
| Male | 67 | 2021 | 123000 | 0.640 |
Why?
|
| Cerebral Ventriculitis | 1 | 2017 | 13 | 0.620 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2019 | 157 | 0.620 |
Why?
|
| Bacteriological Techniques | 2 | 2016 | 121 | 0.610 |
Why?
|
| Prostatic Diseases | 1 | 2017 | 30 | 0.600 |
Why?
|
| Prostheses and Implants | 1 | 2019 | 295 | 0.590 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 11 | 2019 | 128 | 0.590 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2017 | 74 | 0.580 |
Why?
|
| Pandemics | 3 | 2022 | 1559 | 0.580 |
Why?
|
| Female | 65 | 2021 | 141928 | 0.570 |
Why?
|
| Molecular Epidemiology | 8 | 2020 | 246 | 0.540 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2016 | 202 | 0.540 |
Why?
|
| Incidence | 11 | 2022 | 5673 | 0.540 |
Why?
|
| Abscess | 1 | 2017 | 177 | 0.530 |
Why?
|
| Sepsis | 4 | 2021 | 652 | 0.530 |
Why?
|
| Membrane Transport Proteins | 3 | 2019 | 244 | 0.510 |
Why?
|
| Streptococcus | 1 | 2015 | 68 | 0.510 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 399 | 0.510 |
Why?
|
| Bacterial Adhesion | 2 | 2010 | 147 | 0.500 |
Why?
|
| Bacterial Typing Techniques | 11 | 2021 | 139 | 0.480 |
Why?
|
| United States | 15 | 2022 | 15433 | 0.470 |
Why?
|
| Crohn Disease | 7 | 2001 | 351 | 0.470 |
Why?
|
| Radiography, Interventional | 1 | 2016 | 305 | 0.470 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 2291 | 0.440 |
Why?
|
| Down Syndrome | 1 | 2015 | 226 | 0.440 |
Why?
|
| Polymerase Chain Reaction | 14 | 2011 | 3203 | 0.400 |
Why?
|
| Prostate | 1 | 2017 | 1088 | 0.400 |
Why?
|
| Genotype | 10 | 2020 | 4109 | 0.400 |
Why?
|
| Chlorhexidine | 3 | 2017 | 88 | 0.390 |
Why?
|
| Enterobacteriaceae Infections | 2 | 2021 | 69 | 0.390 |
Why?
|
| Paratuberculosis | 3 | 2000 | 15 | 0.390 |
Why?
|
| Vancomycin | 5 | 2018 | 273 | 0.390 |
Why?
|
| Population Surveillance | 3 | 2018 | 627 | 0.380 |
Why?
|
| In Situ Hybridization | 4 | 2001 | 1037 | 0.380 |
Why?
|
| Diabetes Complications | 1 | 2012 | 305 | 0.360 |
Why?
|
| Retrospective Studies | 24 | 2019 | 37905 | 0.360 |
Why?
|
| Nasal Cavity | 1 | 2011 | 149 | 0.350 |
Why?
|
| Bacterial Proteins | 7 | 2019 | 1029 | 0.320 |
Why?
|
| Prospective Studies | 11 | 2021 | 12873 | 0.320 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2008 | 36 | 0.320 |
Why?
|
| DNA, Bacterial | 12 | 2021 | 558 | 0.310 |
Why?
|
| Azithromycin | 3 | 1997 | 78 | 0.310 |
Why?
|
| Chlamydophila pneumoniae | 2 | 1997 | 12 | 0.300 |
Why?
|
| Prevalence | 6 | 2018 | 3260 | 0.280 |
Why?
|
| Staphylococcal Skin Infections | 4 | 2014 | 53 | 0.260 |
Why?
|
| Mupirocin | 3 | 2015 | 25 | 0.250 |
Why?
|
| Antigens, Bacterial | 4 | 2001 | 354 | 0.250 |
Why?
|
| Disease Outbreaks | 6 | 2022 | 415 | 0.250 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2005 | 87 | 0.240 |
Why?
|
| Streptococcus pyogenes | 2 | 2023 | 119 | 0.240 |
Why?
|
| Penicillins | 3 | 2023 | 143 | 0.220 |
Why?
|
| Clarithromycin | 3 | 1997 | 119 | 0.220 |
Why?
|
| Young Adult | 12 | 2021 | 21445 | 0.220 |
Why?
|
| Chi-Square Distribution | 5 | 2013 | 1323 | 0.220 |
Why?
|
| Amoxicillin | 2 | 2020 | 106 | 0.210 |
Why?
|
| Mastoiditis | 2 | 2015 | 26 | 0.210 |
Why?
|
| Body Fluids | 1 | 2023 | 125 | 0.210 |
Why?
|
| Enterobacter | 1 | 2021 | 20 | 0.210 |
Why?
|
| Cronobacter sakazakii | 1 | 2021 | 5 | 0.210 |
Why?
|
| Databases, Factual | 2 | 2019 | 2218 | 0.210 |
Why?
|
| Fixatives | 1 | 2021 | 28 | 0.200 |
Why?
|
| RNA, Ribosomal, 16S | 6 | 2019 | 490 | 0.200 |
Why?
|
| Spheroplasts | 1 | 2000 | 4 | 0.200 |
Why?
|
| Formaldehyde | 1 | 2021 | 114 | 0.190 |
Why?
|
| Cattle Diseases | 1 | 2000 | 22 | 0.190 |
Why?
|
| Cell Wall | 1 | 2000 | 46 | 0.190 |
Why?
|
| Infant Formula | 1 | 2021 | 91 | 0.190 |
Why?
|
| Helicobacter | 2 | 1998 | 14 | 0.190 |
Why?
|
| Rifabutin | 1 | 2020 | 25 | 0.190 |
Why?
|
| Immunization Schedule | 2 | 2019 | 117 | 0.190 |
Why?
|
| Double-Blind Method | 3 | 2021 | 2588 | 0.190 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2020 | 67 | 0.180 |
Why?
|
| Water Supply | 2 | 1998 | 24 | 0.180 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 63 | 0.180 |
Why?
|
| Virus Diseases | 2 | 2022 | 398 | 0.180 |
Why?
|
| Omeprazole | 1 | 2020 | 92 | 0.180 |
Why?
|
| Coinfection | 1 | 2021 | 189 | 0.170 |
Why?
|
| Enterobacter cloacae | 1 | 2018 | 28 | 0.170 |
Why?
|
| Enterococcus | 1 | 2019 | 59 | 0.170 |
Why?
|
| Phylogeny | 3 | 2022 | 826 | 0.170 |
Why?
|
| Bacteroides | 1 | 2019 | 42 | 0.170 |
Why?
|
| Staphylococcus | 1 | 2019 | 86 | 0.170 |
Why?
|
| Public Health | 1 | 2021 | 299 | 0.170 |
Why?
|
| Sequence Analysis, DNA | 7 | 2020 | 2483 | 0.170 |
Why?
|
| Antiporters | 1 | 2019 | 71 | 0.170 |
Why?
|
| DNA Transposable Elements | 1 | 2020 | 222 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2016 | 6550 | 0.160 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 527 | 0.160 |
Why?
|
| Bone Diseases, Infectious | 1 | 2018 | 12 | 0.160 |
Why?
|
| Ranitidine | 1 | 1997 | 35 | 0.160 |
Why?
|
| Treatment Outcome | 11 | 2021 | 32848 | 0.160 |
Why?
|
| Immunocompromised Host | 3 | 2019 | 698 | 0.160 |
Why?
|
| Medical Records | 1 | 2019 | 415 | 0.160 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2019 | 149 | 0.160 |
Why?
|
| Health Care Surveys | 1 | 2019 | 430 | 0.160 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1997 | 70 | 0.150 |
Why?
|
| Water Microbiology | 2 | 1998 | 22 | 0.150 |
Why?
|
| Anti-Ulcer Agents | 1 | 1997 | 101 | 0.150 |
Why?
|
| Bacterial Capsules | 1 | 2016 | 39 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2016 | 9244 | 0.140 |
Why?
|
| Ceftriaxone | 1 | 2016 | 67 | 0.140 |
Why?
|
| Comorbidity | 4 | 2017 | 2352 | 0.140 |
Why?
|
| Adult | 16 | 2021 | 77950 | 0.140 |
Why?
|
| Patient Admission | 1 | 2018 | 220 | 0.140 |
Why?
|
| RNA, Bacterial | 2 | 2012 | 80 | 0.140 |
Why?
|
| Statistics, Nonparametric | 4 | 2013 | 980 | 0.140 |
Why?
|
| Skin | 2 | 2020 | 1259 | 0.140 |
Why?
|
| Doxycycline | 1 | 1997 | 178 | 0.140 |
Why?
|
| Biopsy | 2 | 2021 | 3443 | 0.140 |
Why?
|
| Colitis | 1 | 2019 | 340 | 0.130 |
Why?
|
| Retropharyngeal Abscess | 1 | 2015 | 11 | 0.130 |
Why?
|
| Mastoid | 1 | 2015 | 26 | 0.130 |
Why?
|
| Endoscopy | 2 | 2014 | 479 | 0.130 |
Why?
|
| Ear, Middle | 1 | 2015 | 48 | 0.130 |
Why?
|
| Twins | 1 | 2015 | 70 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 544 | 0.130 |
Why?
|
| Otitis Media | 1 | 2015 | 65 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1997 | 1489 | 0.120 |
Why?
|
| Sodium Hypochlorite | 1 | 2013 | 12 | 0.120 |
Why?
|
| Baths | 1 | 2013 | 16 | 0.120 |
Why?
|
| Hygiene | 1 | 2013 | 24 | 0.120 |
Why?
|
| Molecular Sequence Data | 5 | 2007 | 6089 | 0.120 |
Why?
|
| Utah | 3 | 2020 | 43 | 0.120 |
Why?
|
| Disease Management | 1 | 2019 | 1052 | 0.120 |
Why?
|
| Disinfection | 1 | 2013 | 42 | 0.120 |
Why?
|
| Lactobacillus | 1 | 2013 | 58 | 0.120 |
Why?
|
| Disinfectants | 1 | 2013 | 35 | 0.120 |
Why?
|
| Aged | 12 | 2021 | 70117 | 0.110 |
Why?
|
| Recurrence | 3 | 2016 | 4758 | 0.110 |
Why?
|
| DNA Fingerprinting | 6 | 2010 | 167 | 0.110 |
Why?
|
| Length of Stay | 2 | 2018 | 1900 | 0.110 |
Why?
|
| Base Sequence | 3 | 2007 | 4917 | 0.110 |
Why?
|
| Antibodies, Bacterial | 2 | 2008 | 380 | 0.110 |
Why?
|
| Glycemic Index | 1 | 2012 | 29 | 0.110 |
Why?
|
| Quinine | 1 | 2012 | 8 | 0.110 |
Why?
|
| Otitis | 1 | 2012 | 8 | 0.110 |
Why?
|
| Sensitivity and Specificity | 6 | 2010 | 4971 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.110 |
Why?
|
| Clindamycin | 3 | 2022 | 50 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 4298 | 0.100 |
Why?
|
| Drug Resistance, Microbial | 4 | 2001 | 218 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Genes, Essential | 1 | 2012 | 48 | 0.100 |
Why?
|
| Middle Aged | 11 | 2021 | 86204 | 0.100 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2011 | 16 | 0.100 |
Why?
|
| Intestinal Mucosa | 1 | 1998 | 1081 | 0.100 |
Why?
|
| Furunculosis | 1 | 2011 | 8 | 0.100 |
Why?
|
| Fractures, Spontaneous | 1 | 2012 | 84 | 0.100 |
Why?
|
| Age Distribution | 2 | 2010 | 698 | 0.100 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 2315 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 2015 | 446 | 0.100 |
Why?
|
| Cattle | 3 | 2000 | 783 | 0.100 |
Why?
|
| Meat | 2 | 2000 | 87 | 0.090 |
Why?
|
| Empyema | 1 | 2009 | 28 | 0.090 |
Why?
|
| Age Factors | 1 | 2019 | 5377 | 0.090 |
Why?
|
| Bacterial Infections | 1 | 2013 | 479 | 0.090 |
Why?
|
| DNA | 1 | 1998 | 2693 | 0.090 |
Why?
|
| Sex Distribution | 1 | 2010 | 495 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2014 | 1819 | 0.080 |
Why?
|
| Environmental Exposure | 1 | 2011 | 288 | 0.080 |
Why?
|
| Genomic Islands | 1 | 2007 | 32 | 0.080 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2014 | 923 | 0.080 |
Why?
|
| Brain | 1 | 2021 | 4113 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 4320 | 0.080 |
Why?
|
| Open Reading Frames | 1 | 2007 | 250 | 0.070 |
Why?
|
| Hydrolases | 1 | 2007 | 123 | 0.070 |
Why?
|
| Virulence | 3 | 2005 | 323 | 0.070 |
Why?
|
| Cluster Analysis | 4 | 2011 | 1053 | 0.070 |
Why?
|
| Catheter-Related Infections | 1 | 2010 | 270 | 0.070 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2008 | 234 | 0.070 |
Why?
|
| Vagina | 1 | 2008 | 317 | 0.070 |
Why?
|
| Risk Factors | 5 | 2021 | 17523 | 0.070 |
Why?
|
| Meningococcal Vaccines | 1 | 2006 | 31 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 5687 | 0.070 |
Why?
|
| Infection Control | 3 | 2015 | 270 | 0.070 |
Why?
|
| Myositis | 1 | 2006 | 79 | 0.070 |
Why?
|
| Plasmids | 1 | 2007 | 837 | 0.070 |
Why?
|
| Health Personnel | 1 | 2011 | 625 | 0.070 |
Why?
|
| Sampling Studies | 1 | 2005 | 170 | 0.060 |
Why?
|
| Aged, 80 and over | 6 | 2013 | 29902 | 0.060 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2008 | 419 | 0.060 |
Why?
|
| Clone Cells | 1 | 2005 | 555 | 0.060 |
Why?
|
| Musculoskeletal Diseases | 1 | 2004 | 81 | 0.060 |
Why?
|
| Spondylitis | 1 | 2002 | 7 | 0.060 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2023 | 49 | 0.060 |
Why?
|
| Probability | 1 | 2005 | 866 | 0.060 |
Why?
|
| Pasteurella Infections | 1 | 2002 | 9 | 0.060 |
Why?
|
| Pasteurella multocida | 1 | 2002 | 12 | 0.060 |
Why?
|
| Fluconazole | 1 | 2002 | 103 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 384 | 0.050 |
Why?
|
| Northern Ireland | 1 | 2022 | 4 | 0.050 |
Why?
|
| Ships | 1 | 2022 | 4 | 0.050 |
Why?
|
| Finland | 1 | 2022 | 55 | 0.050 |
Why?
|
| Norway | 1 | 2022 | 30 | 0.050 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2002 | 44 | 0.050 |
Why?
|
| Wound Infection | 1 | 2002 | 54 | 0.050 |
Why?
|
| Chemokine CXCL10 | 1 | 2022 | 105 | 0.050 |
Why?
|
| Nitroreductases | 1 | 2001 | 6 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 1450 | 0.050 |
Why?
|
| Animals | 7 | 2019 | 59536 | 0.050 |
Why?
|
| Thoracic Vertebrae | 1 | 2002 | 186 | 0.050 |
Why?
|
| Cephalosporins | 1 | 2022 | 148 | 0.050 |
Why?
|
| Candida albicans | 1 | 2002 | 175 | 0.050 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2002 | 82 | 0.050 |
Why?
|
| Mycobacterium avium Complex | 1 | 2001 | 29 | 0.050 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2001 | 31 | 0.050 |
Why?
|
| Genome, Bacterial | 1 | 2022 | 200 | 0.050 |
Why?
|
| Muramidase | 1 | 2000 | 110 | 0.050 |
Why?
|
| Phylogeography | 1 | 2020 | 16 | 0.050 |
Why?
|
| Poland | 1 | 2020 | 61 | 0.050 |
Why?
|
| Candidiasis | 1 | 2002 | 262 | 0.050 |
Why?
|
| South Africa | 1 | 2020 | 92 | 0.050 |
Why?
|
| Occupational Exposure | 1 | 2022 | 244 | 0.040 |
Why?
|
| Sarcoidosis | 1 | 2000 | 112 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 6009 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2005 | 717 | 0.040 |
Why?
|
| Photography | 1 | 2000 | 139 | 0.040 |
Why?
|
| HIV Infections | 1 | 2012 | 2134 | 0.040 |
Why?
|
| DNA, Ribosomal | 2 | 2013 | 103 | 0.040 |
Why?
|
| Dextran Sulfate | 1 | 2019 | 72 | 0.040 |
Why?
|
| Cell Line | 2 | 1997 | 5114 | 0.040 |
Why?
|
| Waste Disposal, Fluid | 1 | 1998 | 4 | 0.040 |
Why?
|
| Fresh Water | 1 | 1998 | 18 | 0.040 |
Why?
|
| Glycine | 1 | 2000 | 289 | 0.040 |
Why?
|
| Lymecycline | 1 | 1997 | 1 | 0.040 |
Why?
|
| Taste Disorders | 1 | 1997 | 17 | 0.040 |
Why?
|
| Respiratory Tract Infections | 1 | 2002 | 437 | 0.040 |
Why?
|
| Autoradiography | 1 | 1998 | 132 | 0.040 |
Why?
|
| Mouth Diseases | 1 | 1997 | 34 | 0.040 |
Why?
|
| Tongue | 1 | 1997 | 77 | 0.040 |
Why?
|
| Videotape Recording | 1 | 1997 | 74 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2001 | 402 | 0.040 |
Why?
|
| Proton Pump Inhibitors | 1 | 2020 | 249 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1997 | 220 | 0.040 |
Why?
|
| Peptic Ulcer | 1 | 1998 | 140 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2012 | 6869 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2000 | 1391 | 0.040 |
Why?
|
| Hospitals | 2 | 2011 | 485 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2020 | 745 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2002 | 834 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 538 | 0.040 |
Why?
|
| Half-Life | 1 | 1996 | 259 | 0.040 |
Why?
|
| Peru | 1 | 1996 | 52 | 0.040 |
Why?
|
| Intracellular Fluid | 1 | 1996 | 45 | 0.040 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2011 | 273 | 0.040 |
Why?
|
| Immunomagnetic Separation | 1 | 1996 | 43 | 0.040 |
Why?
|
| Extracellular Space | 1 | 1996 | 132 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2019 | 324 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 834 | 0.030 |
Why?
|
| Neoplasms | 3 | 2013 | 15193 | 0.030 |
Why?
|
| Nausea | 1 | 1997 | 525 | 0.030 |
Why?
|
| Feces | 1 | 2019 | 770 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1996 | 542 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1996 | 503 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2015 | 73 | 0.030 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 1998 | 301 | 0.030 |
Why?
|
| Bacteria | 1 | 2019 | 611 | 0.030 |
Why?
|
| Intestine, Small | 1 | 1998 | 499 | 0.030 |
Why?
|
| Gastritis | 1 | 1998 | 373 | 0.030 |
Why?
|
| Diarrhea | 1 | 1997 | 686 | 0.030 |
Why?
|
| Acute Disease | 2 | 2012 | 2422 | 0.030 |
Why?
|
| Eczema | 1 | 2013 | 37 | 0.030 |
Why?
|
| Blood | 1 | 2014 | 156 | 0.030 |
Why?
|
| Diterpenes | 1 | 2014 | 111 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2000 | 1818 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1998 | 2063 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2013 | 409 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 1997 | 589 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1998 | 600 | 0.030 |
Why?
|
| Inflammation | 2 | 2019 | 2522 | 0.030 |
Why?
|
| Bedding and Linens | 1 | 2011 | 10 | 0.030 |
Why?
|
| Hospital Design and Construction | 1 | 2011 | 12 | 0.030 |
Why?
|
| Bacillus | 1 | 2011 | 37 | 0.030 |
Why?
|
| Genomics | 1 | 2022 | 2738 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2012 | 297 | 0.020 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2011 | 16 | 0.020 |
Why?
|
| Molecular Typing | 1 | 2011 | 55 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2001 | 2819 | 0.020 |
Why?
|
| Prognosis | 2 | 2006 | 21713 | 0.020 |
Why?
|
| Penicillin-Binding Proteins | 1 | 2010 | 12 | 0.020 |
Why?
|
| Synovial Fluid | 1 | 2009 | 27 | 0.020 |
Why?
|
| Sequence Homology | 1 | 2009 | 71 | 0.020 |
Why?
|
| Viral Load | 1 | 2012 | 493 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2022 | 4549 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2000 | 568 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2000 | 3719 | 0.020 |
Why?
|
| Immunoassay | 1 | 2010 | 216 | 0.020 |
Why?
|
| Rats | 1 | 1998 | 6086 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 6942 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 672 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 9180 | 0.020 |
Why?
|
| Temporal Bone | 1 | 2008 | 102 | 0.020 |
Why?
|
| Time Factors | 2 | 2015 | 12926 | 0.020 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2006 | 28 | 0.020 |
Why?
|
| Premature Birth | 1 | 2011 | 407 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 7222 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 1997 | 2278 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 1021 | 0.020 |
Why?
|
| Gentamicins | 1 | 2004 | 90 | 0.020 |
Why?
|
| Rifampin | 1 | 2004 | 191 | 0.010 |
Why?
|
| Sorbitol | 1 | 2002 | 28 | 0.010 |
Why?
|
| Demography | 1 | 2004 | 435 | 0.010 |
Why?
|
| Trehalose | 1 | 2002 | 23 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2005 | 829 | 0.010 |
Why?
|
| Random Amplified Polymorphic DNA Technique | 1 | 2002 | 9 | 0.010 |
Why?
|
| Genes, rRNA | 1 | 2002 | 22 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2006 | 329 | 0.010 |
Why?
|
| Infant, Premature | 1 | 2007 | 787 | 0.010 |
Why?
|
| DNA, Fungal | 1 | 2002 | 127 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2006 | 1544 | 0.010 |
Why?
|
| Debridement | 1 | 2002 | 123 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2012 | 6100 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2002 | 362 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 2049 | 0.010 |
Why?
|
| Food Contamination | 1 | 2001 | 22 | 0.010 |
Why?
|
| Spinal Cord Compression | 1 | 2002 | 151 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2004 | 1313 | 0.010 |
Why?
|
| Sex Factors | 1 | 2006 | 2139 | 0.010 |
Why?
|
| Metronidazole | 1 | 2001 | 149 | 0.010 |
Why?
|
| Mutation | 1 | 2000 | 15179 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2000 | 629 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2000 | 266 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 997 | 0.010 |
Why?
|
| Vaccination | 1 | 2006 | 1123 | 0.010 |
Why?
|
| Hospitals, Veterans | 1 | 2002 | 397 | 0.010 |
Why?
|
| Leprosy | 1 | 1999 | 33 | 0.010 |
Why?
|
| Rabbits | 1 | 2000 | 957 | 0.010 |
Why?
|
| Sweden | 1 | 1998 | 70 | 0.010 |
Why?
|
| Milk, Human | 1 | 2001 | 277 | 0.010 |
Why?
|
| Phenotype | 2 | 2002 | 6295 | 0.010 |
Why?
|
| Magnetics | 1 | 1998 | 107 | 0.010 |
Why?
|
| Survival Rate | 1 | 2011 | 12221 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1999 | 886 | 0.010 |
Why?
|
| Tetracycline | 1 | 1997 | 90 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1998 | 844 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 14889 | 0.010 |
Why?
|
| Pregnancy | 1 | 2008 | 7573 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 4233 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2002 | 830 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 2927 | 0.010 |
Why?
|
| Tuberculosis | 1 | 1999 | 548 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 7551 | 0.010 |
Why?
|